Dublin, Oct. 31, 2022 (GLOBE NEWSWIRE) -- The "mRNA Vaccines and RNAi Therapeutics Market By Disease Type, By Route of administration, By End user: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
The single protein-coding gene known as messenger ribonucleic acid (mRNA) is located in the genome and provides the basis for how cells make proteins. Mammalian cells are used in the laboratory to create mRNA vaccines and treatments, which have positive immunological properties. Some of the most common types of vaccines and therapies include non-replicating, in vivo self-replicating, self-amplifying, and in-vitro dendritic cell non-replicating mRNA. They are administered intravenously to trigger the immune system's virus-detection mechanisms and trigger the production of viral antigen proteins by the cells. The body's immunity is strengthened through enhancing B- and T-cell responses.
The major factors that drive the growth of the global mRNA vaccines and RNAi therapeutics market include increase in awareness about vaccination, increase in prevalence of cancer and cardiovascular disease and initiatives taken by government for large scale sequencing projects.
In addition, target specialty and selectivity of treatment further propel the market growth. However, high cost of research, threat of failure and challenges in quantification of mRNA are expected to restrain the growth of the mRNA vaccines and RNAi therapeutics market during the forecast period. Conversely, application of mRNA technology and development of mRNA biomarker are anticipated to provide lucrative opportunities to the market players.
The mRNA vaccines and RNAi therapeutics market is segmented into disease type, route of administration, end user and region. According to disease type, the market is categorized into hereditary transthyretin-mediated amyloidosis genetic, acute hepatic porphyria, primary hyperoxaluria type 1 and atherosclerotic cardiovascular disease. On the basis of route of administration, it is segmented into IV infusion and subcutaneous. By end user, it is segregated into research institute and hospitals and clinics. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mRNA vaccines and RNAi therapeutics market analysis from 2021 to 2031 to identify the prevailing mrna vaccines and rnai therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the mRNA vaccines and RNAi therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global mRNA vaccines and RNAi therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Disease Type
Hereditary transthyretin-mediated amyloidosis genetic
Acute hepatic porphyria
Primary hyperoxaluria type 1
Atherosclerotic cardiovascular disease
By Route of administration
By End user
Hospitals and clinics
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
Key Market Players
Sangamo Therapeutics, Inc.
SCM Life Sciences (Argos Therapeutics, Inc. )
Ionis Pharmaceuticals, Inc
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY DISEASE TYPE
CHAPTER 5: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
CHAPTER 6: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY END USER
CHAPTER 7: MRNA VACCINES AND RNAI THERAPEUTICS MARKET, BY REGION
CHAPTER 8: COMPANY LANDSCAPE
CHAPTER 9: COMPANY PROFILES
For more information about this report visit https://www.researchandmarkets.com/r/ey5ssw
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900